SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
GERN Analysis & Videos »
GERN: Bull or Bear?
BioMed Momentum Index: Pause that Refreshes or More Pain to Come?
GERN
|
|
|
-0.52%
in
40 days
Below is a 10-stock BioMed Momentum Index that I have created along with related financial data from Google Finance as of 10/28/09, including the stock price, 52-week change, average daily trading volume, and market cap. I have screened for small and micro-cap stocks with market caps of approximately $500 million (M) or lower with stock price increases of at least 50% in the past year and average trading volume of at least 1M shares per day. <> 1.) Antigenics (NASDAQ: AGEN) ($...
|
Stem Cell Index Surges in Past Week
GERN
|
|
|
-7.70%
in
172 days
(closed on 10/29/09)
<> The stem cell trade was back in a big way over the past week, with several stocks in the <font> ETF Innovators Stem Cell Index </font> registering impressive gains, compared to market and biotech ETF benchmarks such as the S&P 500 SPDR (NYSE:SPY) +6%, iShares Nasdaq Biotech (NASDAQ:IBB) +2%, SPDR S&P Biotech (NYSE:XBI +4%). Hot stocks over the past week among the 40 component companies in the stem cell index include NeoStem (AMEX:NBS) +52.2%, Cytori Therapeutics (NASDAQ:CYTX) +37%, and Geron (NASDAQ:GERN) +22%. Two other widely followed stocks from the index registered smaller gains,...
|
Bullish on GERN ...
GERN
|
|
|
+29.31%
in
259 days
Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. The company develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines, as well as focuses on the development of products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening. Its products include GRN163 and GRN163L, which are telomerase inhibitors for the treatment of c...
|
Analysis of Global Stem Cell Index YTD
GERN
|
|
|
+12.07%
in
6 days
(closed on 03/10/09)
The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index , which is down 13.8% at a value of 3,387 from a 2/22/09 inception date value of 3,928. The index is down 30.6% over the past year on an equal-weight basis, compared to losses of 31.2% for the Healthcare Sector SPDR (XLV), 19% for iShares Nasdaq Biotech (IBB), 14.7% for SPDR S&P Biotech (XBI), 29.7% for PowerShares Biotech & Genome (PBE), and 46.1% for the S&P 500 SPDR (SPY). <> Below is a profile for each company, including a summary of their b...
|
Global Stem Cell and Regenerative Medicine Index
GERN
|
|
|
-26.05%
in
7 days
(closed on 03/04/09)
By Mike Havrilla on 2/25/09
www.BioMedReports.com The ETF Innovators Global Stem Cell and Regenerative Medicine Index includes 40 companies with market caps less than $1B at the index inception and the total market value of the index will be tracked as a gauge of investor and trader sentiment toward stem cell companies from a starting value of 3,928 on 2/22/09 and current value of 3,860 as of 2/25/09 - down 1.7% from the closing value last week. <> <> The index is down 23.8% over the past year on an equal-weight basis, compared to losses of 21.4% for the Heal...
|
Global Stem Cell Index Down 9% Last Week
GERN
|
|
|
+3.00%
in
3 days
(closed on 02/25/09)
Global Stem Cell Index Down 9% Last Week By Mike Havrilla on 2/21/09 The ETF Innovators Global Stem Cell and Regenerative Medicine Index of 40 companies with market caps less than $1B at the index inception lost 9% of its value last week and is down 24.8% over the past year on an equal-weight basis, compared to losses of 21.6% for the Healthcare Sector SPDR (XLV), 8.4% for iShares Nasdaq Biotech (IBB), 4.5% for SPDR S&P Biotech (XBI), 19.9% for PowerShares Biotech & Genome (PBE), and 41.6% for the S&P 500 SPDR (SPY).
|
Global Stem Cell and Regenerative Medicine Index
GERN
|
|
|
-15.13%
in
4 days
(closed on 02/22/09)
Global Stem Cell and Regenerative Medicine Index By Mike Havrilla on 2/17/09 <> The table at my website link below includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously . The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close today. As previously, I will track the total market value for a more comprehensive gauge of investor sentiment...
|
Stem Cell Index Down 1% in Past Week
GERN
|
|
|
-18.04%
in
7 days
(closed on 02/16/09)
Stem Cell Index Down 1% in Past Week By Mike Havrilla on 2/9/09 ETF Innovators, LLP <> The table at my website link below includes 29 companies in the ETF Innovators (ETFI) Emerging Stem Cell Index, which lost about 1% of market value in the past week and posted an 8.5% loss over the past year on an equal-weight basis. Results for benchmark indexes and ETFs include gains of 1.5% for SPDR S&P Biotech (XBI) and 1.2% for the ETFI Cosmetic and Reconstructive Medicine Index and losses of 17.4% for Healthcare Sector SPDR (XLV), 3.7% for iShares Nasdaq Biotech (IBB), a...
|
New Emerging Stem Cell Index
GERN
|
|
|
+8.67%
in
7 days
(closed on 02/09/09)
New Emerging Stem Cell Index Shares of Geron (GERN) and other well known stem cell and regenerative medicine stocks such as Osiris Therapeutics (OSIR) and StemCells (STEM) have been soaring since the FDA allowed human clinical testing for Geron's embryonic stem cell treatment candidate for spinal cord injuries. <> The table at my website link below highlights 25 U.S.-listed stem cell and regenerative medicine companies with market caps of below $200M which are included in the ETF Innovators Emerging Stem Cell Index. The companies are also listed below in descending ...
|
Missed the stem cell move? Make a play at Jacobs Engineering
GERN
-22.62%
in
318 days
Filed under: Stocks to Buy, StemCells Inc. (STEM) Do not underestimate the power of a new administration in Washington. With the ability to spend a huge amount of dollars, team Obama can wield tremendous influence in the market. Case in point is the stem cell space. It is widely expected that Obama will issue an executive order eliminating restrictions on stem cell research. Stocks like StemCells Inc. (NASDAQ: STEM) and Geron Corp. (NASDAQ: GERN) have been moving higher since the inaugural. <>Coincidentally, on Friday, GERN announced approval for human trials for its treatment of spinal chord in...
|
Trading the Trials and FDA Decision Calendar
GERN
|
|
|
+0.40%
in
9 days
(closed on 02/02/09)
Trading the Trials and FDA Decision Calendar The tables at my website links below feature an updated calendar of 80 expected FDA new product decisions and 89 pending clinical trial result estimates + pending FDA re-submissions. Click here for a link to my previous FDA calendars and click here for a list of 14 extreme trades of companies with market caps below $100M and pending new drug decisions at the FDA. <> Below is a summary of the major updates on the calendar...
|
Index to Track New Era for Stem Cell Cos.
GERN
|
|
|
-5.92%
in
19 hours
(closed on 01/24/09)
Index to Track New Era for Stem Cell Cos. Shares of Geron (GERN) are soaring today by more than 40% on FDA approval to begin human clinical testing this summer for an embryonic stem cell treatment for spinal cord injuries. The approval comes just days after the new administration took office, breathing new life into related companies such as StemCells (STEM), Aastrom Biosciences (ASTM), and others tracked in the ETF Innovators Cosmetic & Reconstructive Medicine Index. <> This index and new ETF idea represents a first-to-market idea to provide investors with an excha...
|
Regenerative Medicine: The Next Frontier for Big Pharma
GERN
|
|
|
+119.94%
in
66 days
(closed on 01/23/09)
<> 
<>
An article last week at the WSJ Health Blog outlined plans by Pfizer (PFE) to begin putting its billions of dollars in cash to use in the emerging field of regenerative medicine and stem cell therapies. Also, an article on Bloomberg identifies GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Novartis (NVS), and Roche (RHHBY) as other healthcare giants as active in regenerative medicine through investments and partnerships.
The move by these healthcare mega-caps comes at a time when credit ...
|
People Bullish on GERN
People Bearish on GERN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on GERN |
EMGE-Stem Cell Play
- I think the significance of this Press Release has been overlooked, and hope the company has more plans to explain its story:
Emergent Health Corp. (E...
|
More Resources
|
About Geron Corp.
- Answers.com
